cefazolin + ceftazidime + ceftriaxone + cefepime + cephalexin + cefaclor + cefadroxil + cefuroxime + cefpodoxime + cefdinir + cefixime

This diagnostic panel consists of eleven cephalosporin antibiotics—cefazolin, ceftazidime, ceftriaxone, cefepime, cephalexin, cefaclor, cefadroxil, cefuroxime, cefpodoxime, cefdinir, and cefixime—utilized by Massachusetts General Hospital in a Phase 2 clinical trial (NCT06406114). The panel is employed for double-blind skin testing and double-blind placebo-controlled drug challenges (DBPCDC) to refine diagnostic protocols for patients with reported cephalosporin allergies. By testing across different generations and side-chain groups, the study aims to characterize cross-reactivity patterns and identify safe alternative beta-lactam antibiotics for allergic individuals. These agents are established small molecule antibiotics that function by inhibiting bacterial cell wall synthesis, but in this context, they serve as diagnostic allergens to evaluate hypersensitivity.

Brand names

RocephinSuprax

Other names

Cephalosporin allergy diagnostic panelMGH cephalosporin allergy testing reagentsOptimizing the Diagnostic Approach to Cephalosporin Allergy Testing panel